BCL2L1 and glioblastoma: In contrast, the pro-apoptotic Bcl-xS variant was significantly inhibited while the anti-apoptotic Bcl-xL variant was upregulated in ASO-transfected GBM cells (ASO1_BCL2L1 and ASO3_BCL2L1) treated with pladienolide B (Fig. 9m).